Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipients

被引:59
作者
Xu, Hong
Chilton, Paula M.
Tanner, Michael K.
Huang, Yiming
Schanie, Carrie L.
Dy-Liacco, Mariano
Yan, Jun
Ildstad, Suzanne T.
机构
[1] Univ Louisville, Inst Cellular Therapeut, Louisville, KY 40202 USA
[2] Univ Louisville, James Graham Brown Canc Ctr, Louisville, KY 40202 USA
关键词
D O I
10.1182/blood-2006-04-017467
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We evaluated the relative contribution of the humoral and cellular arms of the immune response to bone marrow cells transplanted into sensitized recipients. We report here for the first time that humoral immunity contributes predominantly to allosensitization. Although the major role for nonmyeloablative conditioning is to control alloreactive host T cells in nonsensitized recipients, strikingly, none of the strategies directed primarily at T-cell alloreactivity enhanced engraftment in sensitized mice. In evaluating the mechanism behind this barrier, we found that humoral immunity plays a critical role in the rejection of allogeneic marrow in sensitized recipients. Adoptive transfer of as little as 25 ILL serum from sensitized mice abrogated engraftment in secondary naive recipients. With the use of mu MT mice as recipients, we found that T-cell-mediated immunity plays a secondary but still significant role in allorejection. Targeting of T cells in sensitized B-cell-deficient mu MT mice enhanced alloengraftment. Moreover, both T- and B-cell tolerance were achieved in sensitized recipients when allochimerism was established, as evidenced by the acceptance of second donor skin grafts and loss of circulating donor-specific Abs. These findings have important implications for the management of sensitized transplant recipients and for xenotransplantation in which B-cell reactivity is a predominant barrier.
引用
收藏
页码:3611 / 3619
页数:9
相关论文
共 35 条
  • [1] Managing the highly sensitized transplant recipient and B cell tolerance
    Baid, S
    Saidman, SL
    Tolkoff-Rubin, N
    Williams, WW
    Delmonico, FL
    Cosimi, AB
    Pascual, M
    [J]. CURRENT OPINION IN IMMUNOLOGY, 2001, 13 (05) : 577 - 581
  • [2] Stem cell transplantation eliminates alloantibody in a highly sensitized patient
    Bartholomew, A
    Sher, D
    Sosler, S
    Stock, W
    Lazda, V
    Koshy, M
    Devine, S
    vanBesien, K
    [J]. TRANSPLANTATION, 2001, 72 (10) : 1653 - 1655
  • [3] BILLINGHAM RE, 1961, FREE SKIN GRAFTING M
  • [4] Bishop GA, 2001, ARCH IMMUNOL THER EX, V49, P129
  • [6] THE FLOW CYTOMETRIC CROSSMATCH - DUAL-COLOR ANALYSIS OF T-CELL AND B-CELL REACTIVITIES
    BRAY, RA
    LEBECK, LK
    GEBEL, HM
    [J]. TRANSPLANTATION, 1989, 48 (05) : 834 - 840
  • [7] Elimination of alloantibodies by immunoablative high dose cyclophosphamide
    Brodsky, RA
    Fuller, AK
    Ratner, LE
    Leffell, MS
    Jones, RJ
    [J]. TRANSPLANTATION, 2001, 71 (03) : 482 - 484
  • [8] Warfarin or low-molecular-weight heparin therapy does not prolong pig-to-primate cardiac xenograft function
    Byrne, GW
    Schirmer, JM
    Fass, DN
    Teotia, SS
    Kremers, WK
    Xu, H
    Naziruddin, B
    Tazelaar, HD
    Logan, JS
    McGregor, CGA
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (05) : 1011 - 1020
  • [9] COLSON YL, 1995, J IMMUNOL, V155, P4179
  • [10] The abrogation of allosensitization following the induction of mixed allogeneic chimerism
    Colson, YL
    Schuchert, MJ
    Ildstad, ST
    [J]. JOURNAL OF IMMUNOLOGY, 2000, 165 (02) : 637 - 644